<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-14T05:33:53Z</responseDate>
  <request identifier="oai:figshare.com:article/34022076" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/34022076</identifier>
        <datestamp>2026-09-29T08:32:38Z</datestamp>
        <setSpec>category_146</setSpec>
        <setSpec>category_7</setSpec>
        <setSpec>category_19</setSpec>
        <setSpec>category_21</setSpec>
        <setSpec>category_873</setSpec>
        <setSpec>category_46</setSpec>
        <setSpec>category_734</setSpec>
        <setSpec>category_122</setSpec>
        <setSpec>category_132</setSpec>
        <setSpec>portal_87</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>Mechanism-based reporting patterns of infection-related adverse events with systemic psoriasis therapies in FAERS</dc:title>
          <dc:creator>Shinwon Hwang (13822820)</dc:creator>
          <dc:creator>Yerim Kwak (25136082)</dc:creator>
          <dc:creator>Yeon Woo Jung (24509015)</dc:creator>
          <dc:creator>Se Yong Jung (13969456)</dc:creator>
          <dc:creator>Jae Il Shin (8112179)</dc:creator>
          <dc:creator>Tae-Gyun Kim (11893628)</dc:creator>
          <dc:subject>Space Science</dc:subject>
          <dc:subject>Medicine</dc:subject>
          <dc:subject>Pharmacology</dc:subject>
          <dc:subject>Biotechnology</dc:subject>
          <dc:subject>Chemical Sciences not elsewhere classified</dc:subject>
          <dc:subject>Immunology</dc:subject>
          <dc:subject>Biological Sciences not elsewhere classified</dc:subject>
          <dc:subject>Mental Health</dc:subject>
          <dc:subject>Infectious Diseases</dc:subject>
          <dc:subject>Psoriasis</dc:subject>
          <dc:subject>FAERS</dc:subject>
          <dc:subject>systemic therapy</dc:subject>
          <dc:subject>biologics</dc:subject>
          <dc:subject>pharmacovigilance</dc:subject>
          <dc:subject>infection</dc:subject>
          <dc:description>&lt;p&gt;Infection-related adverse events are an important safety concern in psoriasis therapy.&lt;/p&gt; &lt;p&gt;To compare infection-related adverse-event reporting across mechanism-based therapy groups.&lt;/p&gt; &lt;p&gt;We analyzed psoriasis-indicated US Food and Drug Administration Adverse Event Reporting System (FAERS) reports from 2014 Q3 through 2025 Q3. Sixteen therapies were grouped as TNF, IL-12/23, IL-17, and IL-23 inhibitors and immunosuppressive or non-immunosuppressive nonbiologics. Primary exposure was a primary- or secondary-suspect listing; sensitivity analysis required drug-sequence linkage to psoriatic disease. Reporting odds ratios (RORs) and information-component lower bounds (IC&lt;sub&gt;025&lt;/sub&gt;) were calculated.&lt;/p&gt; &lt;p&gt;Among 357,728 reports, 67,827 contained an infection term. Signals were strongest for immunosuppressive nonbiologics (ROR 2.51; IC&lt;sub&gt;025&lt;/sub&gt; 0.88) and IL-12/23 inhibition (2.43; 0.83), followed by IL-17 inhibitors (1.82; 0.47). TNF inhibitors showed a modest signal (1.17; 0.11), whereas IL-23 inhibitors were near null (0.99; −0.04). Indication linkage attenuated the immunosuppressive-nonbiologic signal to ROR 1.14 (IC&lt;sub&gt;025&lt;/sub&gt; 0.09), while IL-12/23 and IL-17 signals persisted. IL-17 inhibitors showed a Candida signal (ROR 8.67; IC&lt;sub&gt;025&lt;/sub&gt; 1.55).&lt;/p&gt; &lt;p&gt;Reporting estimates varied by mechanism, and exposure attribution materially influenced the immunosuppressive-nonbiologic result.&lt;/p&gt;</dc:description>
          <dc:date>2026-09-29T08:32:38Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.6084/m9.figshare.34022076.v1</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/Mechanism-based_reporting_patterns_of_infection-related_adverse_events_with_systemic_psoriasis_therapies_in_FAERS/34022076</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
